Top

Clinical and Translational Oncology

Published in:

01-01-2015 | Research Article

Prognostic and predictive value of plasma D-dimer in advanced non-small cell lung cancer patients undergoing first-line chemotherapy

Authors: L.-P. Ge, J. Li, Q.-L. Bao, P. Chen, Q. Jiang, L.-R. Zhu

Published in: Clinical and Translational Oncology | Issue 1/2015

Abstract

Purpose

Previous studies have demonstrated that plasma D-dimer, a degradation product of cross-linked fibrin, correlated with tumor stage and prognosis in cancer patients. The aim of this study is to examine whether plasma D-dimer levels before and during chemotherapy predict tumor response and survival in advanced NSCLC patients undergoing first line chemotherapy.

Methods

Plasma D-dimer levels before (B0), and after one (B1) and two (B2) cycles of chemotherapy in 82 patients with advanced NSCLC were measured and correlated with treatment response, clinical features, progression-free survival (PFS) and overall survival.

Results

A significant correlation was identified between changes in D-dimer levels before and after two chemotherapy cycles and treatment response. In addition, there were significant correlations between D-dimer positivity at B0, B1 and B2 time points and tumor stage, number of metastatic sites and treatment response. Patients with positivity of D-dimer at B0, B1 and B2 had significantly shorter PFS compared with those with negativity. Notably, positivity of D-dimer at B1 and B2 time points was an independent predictive factor for unfavorable PFS.

Conclusions

The positivity of D-dimer before and during chemotherapy is a predictor of treatment response and worse PFS in patients with advanced NSCLC. D-dimer levels provide prognostic information in addition to that of imaging studies.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.PubMedCrossRef

Jett JR, Schild SE, Keith RL, Kesler KA. Treatment of non-small cell lung cancer, stage IIIB ACCP evidence-based clinical practice guidelines (2nd edn). Chest. 2007;132(suppl):266s–76s.PubMedCrossRef

Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, et al. Treatment of non-small cell lung cancer, stage IV ACCP evidence-based clinical practice guidelines (2nd edn). Chest. 2007;132(suppl):277s–89s.PubMedCrossRef

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kapalan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and treatment of cancer, National Cancer Institute of the United states, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef

Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer. 2006;107:2842–9.PubMedCrossRef

Ishiguro F, Fukui T, Mori S, Katayama T, Sakakura N, Hatooka S, et al. Serum carcinoembryonic antigen levels as a surrogate marker for the evaluation of lung response to chemotherapy in nonsmall cell lung cancer. Ann Thorac Cardiovasc Surg. 2010;16:242–7.PubMed

Indovina P, Marcelli E, Maranta P, Tarro G. Lung Cancer proteomics: recent advances in biomarker discovery. Int J Proteomics 2011;2011:1–7. doi:10.1155/2011/726869.

Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009;27:4821–6.PubMedCentralPubMedCrossRef

Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulabe state of malignancy: pathogenesis and current debate. Neoplasia. 2002;4:465–73.PubMedCentralPubMedCrossRef

10.

Falanga A, Panove-Noeva M, Russo L. Procoagulant mechanism in tumor-cells. Best Pract Res Clin Haematol. 2009;22:49–60.PubMedCrossRef

11.

Kvolik S, Jukic M, Matijevic M, Marjanovic K, Glavas-Obrovac L. An Overview of coagulation disorders in cancer patients. Surg Oncol. 2010;19:33–46.CrossRef

12.

Lippi G, Franchini M, Targher G, Favaloro EJ. Help me, doctor! My D-dimer is raised. Ann Med. 2008;40:594–605.PubMedCrossRef

13.

Batschauer APB, Figueiredo CP, Bueno EC, Ribeiro MA, Dusse LMS, Fernandes AP, et al. D-Dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol. 2010;21:1267–72.PubMedCrossRef

14.

Blackwell K, Haroon Z, Broadwater G, Berry O, Harris L, Iglehart JD, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol. 2000;18:600–8.PubMed

15.

Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer. 2002;86:389–95.PubMedCentralPubMedCrossRef

16.

Kwon H-C, Oh SY, Lee S, Kim S-H, Han JY, Koh RY, et al. Plasma levels of prothrombin fragment F1 + 2, D-dimer and prothrombin time correlate with clinical stage and lymph node metastasis in operable gastric cancer patients. Jpn J Clin Oncol. 2008;38:2–7.PubMedCrossRef

17.

Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer levels is associated with advanced tumor stage and shorter survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol. 2001;31:388–94.PubMedCrossRef

18.

Blackwell K, Hurcvitz H, Lieberm G, Novotny W, Snyder S, Dewhirst M, et al. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer. 2004;101:77–82.PubMedCrossRef

19.

Gadducci A, Baicchi U, Marrai R, Facchini V, del Bravo B, Fosella PV, et al. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with operable cervical cancer: influence of surgical-pathological stage, tumor size, histologic type, and lymph node status. Gynecol Oncol. 1993;49:354–8.PubMedCrossRef

20.

Khoury JD, Adcock DM, Chan F, Symanowski JT, Tiefenbacher S, Goodman O, et al. Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer. Am J Clin Pathol. 2010;134:964–9.PubMedCrossRef

21.

Hong SK, Ko DW, Park J, Kim IS, Doo SH, Yoon CY, et al. Alteration of antithrombin III and D-dimer levels in clinically localized prostate cancer. Korean J Urol. 2010;51:25–9.PubMedCentralPubMedCrossRef

22.

Tomimaru Y, Yano M, Takachi K, Kishi K, Miyashiro I, Ohue M, et al. Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer. J Am Coll Surg. 2006;202:139–45.PubMedCrossRef

23.

Diao D, Zhu K, Wang Z, Cheng Y, Li K, Pei L, et al. Prognostic value of the D-dimer test in oesophageal cancer during the perioperative period. J Surg Oncol. 2013;108:34–41.PubMedCrossRef

24.

Antoniou D, Pavlakou G, Stathopoulos GP, Karydis I, Chondrou E, Papageorgiou C, et al. Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer. 2006;53:205–10.PubMedCrossRef

25.

Altiay G, Ciftci A, Demir M, Kocak Z, Sut N, Tabakoglue, et al. High Plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol. 2007;19:494–8.CrossRef

26.

Zhang PP, Sun JW, Wang XY, Liu XM, Li K. Preoperative plasma D-dimer levels predict survival in patients with operable non-small cell lung cancer independently of venous thromboembolism. Eur J Surg Oncol. 2013;39:951–6.PubMedCrossRef

27.

Baccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma clinical and prognostic significance. Cancer. 2003;97:3044–52.CrossRef

28.

Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation test in lung cancer. Eur Respir J. 2001;17:667–73.PubMedCrossRef

Title: Prognostic and predictive value of plasma D-dimer in advanced non-small cell lung cancer patients undergoing first-line chemotherapy
Authors: L.-P. Ge
J. Li
Q.-L. Bao
P. Chen
Q. Jiang
L.-R. Zhu
Publication date: 01-01-2015
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 1/2015
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-014-1198-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain

EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma

Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology

Interleukin-17 is a favorable prognostic marker for colorectal cancer

Acknowledgement to Referees 2014

Indirect comparisons in cost-effectiveness analysis: are we being naïve?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer